Pilocarpine hydrochloride has been reported to increase salivation and decrease oral mucositis in patients receiving head and neck radiotherapy, but there is only one report of its use in a cancer chemotherapy patient population. This prospective, double-blinded, randomized, placebo-controlled trial was undertaken to determine the efficacy of pilocarpine for the moderation of oral mucositis during autologous blood stem cell transplantation. Subjects were randomized to receive a 5 mg tablet of pilocarpine, or a placebo, during and following chemotherapy. Subjects were seen every other day and evaluated for gingival, oral, and oropharyngeal mucositis; nutrition; oral hygiene; eating; speaking; sleeping; pain at rest and/or with swallowing; and mouth dryness. We recorded the mean and highest scores and duration of problems, along with white blood cell counts and differentials, and the use of systemic narcotics for oral mucosal pain. We enrolled and randomized 36 subjects, and there were no statistically or clinically significant differences for the primary outcome of severity of mucositis and no clinically significant differences in any of the other outcome measures. Pilocarpine has no benefit for the moderation of the incidence, severity, or duration of mucositis in patients receiving autologous blood stem cell transplantation. Bone Marrow Transplantation (2005) 35, 713-720.
saliva
Oral and oropharyngeal mucositis (inflammation) are common dose-limiting side effects of high-dose chemotherapy, and are more likely with certain chemotherapy agents and more aggressive protocols.
1 Mucositis can lead to ulceration, secondary infection, chronic bacteremia, gingival bleeding, pain requiring parenteral narcotics, total parenteral nutrition, extended and more costly hospitalization, and quality of life issues (eg, problems with dysphagia, chronic pain, sleep, and speech). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Although the pathophysiology of mucositis and the breakdown of mucosal tissues from chemotherapy is speculative and more complex than originally thought, several factors are involved. [13] [14] [15] [16] [17] Immunosuppression likely changes the volume and diversity of bacteria that exist in a delicate ecological balance in the dark, warm, moist environment of the mouth. Little is known about the effect of cancer chemotherapeutic agents on human salivary gland tissue, and the individual constituents of saliva. There appears to be a decrease in the production of saliva, with a presumed decrease in its protective properties, which include clearing a large burden of bacteria from the mouth. [18] [19] [20] [21] [22] [23] Finally, mechanical, thermal, or chemical injury to the mucosa increases the likelihood of inflammation and ulceration.
The management of oral mucositis remains palliative. Inspite of clinical trials of various agents, there have been few significant advances in the prevention or management of mucositis since the introduction of myelosuppressive chemotherapy over 40 years ago. [24] [25] [26] To date, only oral cryotherapy had been shown in randomized trials to reduce the incidence of chemotherapy-induced mucositis, and only in specific patient populations. [27] [28] [29] Pilocarpine is a cholinergic, parasympathomimetic agent with a broad spectrum of action, and predominant muscarinic activity. 30 It causes increased secretion by exocrine glands, including sweat, salivary, lacrimal, gastric, pancreatic, and intestinal, as well as the mucosal cells of the respiratory and vaginal tracts. 31 With the current formulation of 5 mg tablets, salivary flow increases within 30 min of administration, 32 peaks at 1 h, and lasts approximately 3-6 h. 30 In prospective, double-blinded, randomized trials, pilocarpine has been reported to increase the volume of salivary flow and reduce complaints of oral dryness when given after high dose radiotherapy that involved the salivary glands. [33] [34] [35] [36] [37] Some reports suggest that head and neck (H&N) cancer patients given pilocarpine during radiotherapy have a reduction of xerostomia, [38] [39] [40] or a decrease in objectively assessed oral/oropharyngeal mucositis and associated pain. 41 However, a recent prospective, double-blind study of H&N radiotherapy patients showed no benefit from pilocarpine in xerostomia, mucositis, or quality of life. 42 There is little information on the potential benefit of pilocarpine in the setting of chemotherapy. Nagler and Nagler 43 reported a significant decrease in xerostomia from chronic graft-versus-host disease (GVHD) following BMT. Leveque et al 44 reported a reduction in mucositis pain and narcotic use in an open label, pilot study of pilocarpine in 16 patients receiving autologous BMT. We could find only one published paper concerning the use of pilocarpine for prevention of chemotherapy-induced oral mucositis, which reported a significant benefit. 45 The primary purpose of this prospective, double-blinded, placebo-controlled trial was to determine the efficacy of oral pilocarpine hydrochloride (Salagen s ) in the moderation of oral mucositis when administered during autologous blood stem cell transplantation (ABSCT).
Materials and methods
Eligible patients between 18 and 65 years of age, planned for ABSCT at our hospital were approached for participation in this study and an institutionally approved consent form was reviewed and signed. Exclusion criteria included: allergy to pilocarpine, salivary gland disease, medications that interfere with the safety and efficacy of pilocarpine (eg, adrenergic antagonists, anticholinergic, and tricyclic drugs), clinically significant asthma (requiring frequent use of inhalers), pregnancy, acute iritis and/or narrowangle glaucoma, or any condition which in the investigator's opinion would contraindicate patient participation in the study. A thorough oral, dental, and radiographic examination was completed, and oral disease was eliminated prior to hospital admission. A power analysis suggested that 17 patients were required in each group to detect an effect size of one, with an a ¼ 0.05, and a power of 80%. Subjects were stratified by cancer diagnosis. Enrollment of 20 subjects for each group was felt to be necessary to allow for any lost to follow-up.
Subjects were stratified according to initial diagnosis and randomized by computer-generated numbering scheme to receive either pilocarpine or an identical-appearing placebo (Table 1) . On the day prior to commencement of total body irradiation (TBI) and/or chemotherapy, subjects received one 5 mg tablet of pilocarpine, or a placebo every 4 h during the day, beginning between 0700 and 0800 h, for a total of four tablets per day. They continued taking these pills until their absolute neutrophil count increased to 500 for at least 48 h or until they were discharged from the hospital. Study evaluations began on day 1 of chemotherapy and occurred every other day until day 10 following transplantation (for the main analysis), or until mucosal recovery, as determined by return to Grade 0 for all mucosal categories listed in the Outcome Measures Grading Scale (Table 2) . We were unable to locate a validated tool for assessment of mucositis that would suit the purpose of this study.
We therefore developed data entry forms to capture relevant subjective and objective data, including toxicity criteria ( Table 2 ). This new tool is a highly modified version of the Southwest Oncology Group (SWOG) toxicity scale. 46 It is comprehensive, quantifiable, and specific to chemotherapy and immunosuppression-related oral problems, especially those that might be prevented or alleviated by experimental intervention. Reliability of the instrument was assessed by having the first 20 patients enrolled in this study examined and scored for mucositis by two different examiners independently, within a 15-min time period. These duplicate evaluations were initiated on day 0, and were continued every other day until resolution of all oral problems or discharge from the hospital. The dual-examiner scores for three anatomic locations -oral, gingival, and oropharyngeal -gave weighted (Cicchetti-Allison) k scores of 0.78, 0.35, and 0.63, respectively. Combining mucositis score from all three locations provided a 'substantial' weighted kappa of 0.68, suggesting that this new tool works well for mucositis in the chemotherapy setting. 47 We determined the overall incidence, severity, and duration of mucositis (ie, erythema and ulceration) utilizing several objective variables, with a focus on three primary anatomical areas -the gingival, oral, and oropharyngeal mucosa. We also gathered objective data on problems with nutrition, oral infection, use of narcotics for mucosal pain, as well as subjective data on problems with oral hygiene, gingival bleeding, eating, speaking, and sleeping (ordinal variables); pain at rest or with swallowing, and mouth dryness (VAS scale) (Tables 2 and 3) .
A review of the first 19 patients to receive ABSCT at our institution prior to this study, some of whom received TBI, revealed that 16 (84%) experienced oral mucositis, and 12 (63%) required an average of 9 days of systemic narcotics for pain control. Mucositis began between day À2 (pretransplant) and day þ 3 (post-transplant), had its highest incidence on day þ 6, and continued until days þ 8 to 13. In an effort to determine accurately the impact of pilocarpine, we selected two time frames following transplantation, days 6-8 and 4-10 that would likely demonstrate a high incidence of mucositis and reveal a potential difference between study groups. We anticipated the most severe mucositis in the narrow time frame (days 6-8). We chose the broader time frame (days 4-10) as the most likely to reveal any differences in mucositis or other chemotherapy-related side effects from pilocarpine. The primary outcome measure was the difference in the severity of mucositis from the broader time frame of Days 4-10. Secondary outcomes included mucositis severity in the more narrow time frame and other measures of mucositis and toxicity (Table 2) . Mucositis incidence and severity were also analyzed over the entire study period from day À1 to study exit. For each mucositis outcome variable, the following were collected: (1) mean score days 4-10; (2) mean score days 6-8; (3) highest grade days 4-10; and (4) duration (days). Finally, we determined a WHO mucositis score derived from the collected data of mucositis and nutrition. 48 The overall mucositis incidence documented the presence of mucositis in any of the three anatomical areas. Primary and secondary end points were measured with 4-point (0-3) or 5-point (0-4) scales, and visual analog scales (0-100 mm) for alternate day assessments.
Standard statistical methods included calculation of means and standard deviations, counts and percentages. For continuous variables, Student's t-test was used if normally distributed, or a Wilcoxon rank-sum test if not normally distributed. The two groups were tested for demographic and baseline differences. The w 2 test or Fisher's exact test was used for dichotomous data. Additionally, area under the curve (AUC) was determined for the following variables: oral, gingival, and oropharyngeal mucositis; and WHO mucositis score. For missing mucositis data points, the last value carried forward was utilized for the determination of AUC. A P-value of less than 0.05 was considered statistically significant. SAS software was employed for all analyses. (SAS Institute Inc., Cary, NC, USA).
Results
A total of 36 patients were enrolled, with 20 randomized to pilocarpine and 16 to the placebo control. No significant differences were noted in baseline characteristics between the two groups (Table 1) . Two subjects in both the pilocarpine and the placebo groups received TBI. Compliance (missed doses) was similar for both groups (Table 3 ). There were no statistically significant differences in the incidence, severity, or duration of mucositis for any of the three anatomic locations (ie, gingival, oral, and oropharyngeal mucosa) during either the broad (days [4] [5] [6] [7] [8] [9] [10] or narrow (days 6-8) time periods, or with the computed WHO mucositis scale (Figure 1) . A secondary analysis for mucositis outcome measures (AUC) was also performed for the entire time frame of the study, day 1 of chemotherapy through hospital discharge, and no significant differences were found. Pain at rest and with swallowing, and use of systemic narcotics were also not significantly different between the groups, nor were reported problems with nutrition, oral hygiene, eating, and speaking ( Figure 2 ). There was a statistically significant increase in sleeping problems in the pilocarpine group for the days 4-10 period (P ¼ 0.03) and a trend towards significance for both the average scores during days 6-8 (P ¼ 0.06) and highest grade Lack of moderation of mucositis by pilocarpine PB Lockhart et al score (P ¼ 0.05). Interestingly, the pilocarpine group also had a trend (P ¼ 0.06) in the days 6-8 mean score for more pronounced xerostomia. There was almost no incidence of gingival bleeding or oral infection in these 36 subjects. There were no differences in side effects between treatment groups, and adverse events were generally mild. In the pilocarpine group, three subjects reported diarrhea, two mental changes, and one heart palpitations. For the placebo group, two subjects reported diarrhea, two dysphagia, two EKG changes, one typhlitis, and one odynophagia.
Discussion
Although the mechanism for, and duration of, damage to the oral mucosa from H&N radiotherapy is different from that induced by chemotherapy, the short-term sequelae are similar. Alterations in salivary function may contribute to oral morbidity with both modalities. Saliva has a variety of beneficial effects on oral and oropharyngeal mucosa, to include lubrication, cleansing, buffering, antimicrobial, mucosal protectant, and hemostatic properties. [18] [19] [20] 22, 23, [49] [50] [51] [52] Chemotherapy-induced changes in human salivary glands and the constituents of saliva have been proposed, 53, 54 but the extent to which a decreased volume of saliva contributes to mucositis, and the extent to which individual elements in saliva are altered in concentration is unclear. 50, 51, [55] [56] [57] [58] [59] A complaint of dry mouth, or xerostomia, is common during chemotherapy administration, although it is unclear to what extent this reflects a true decrease in salivary flow, or is the result of the influence of other medications (eg, antinausea), an indirect effect such as dehydration, or simply a subjective sensation of dryness. Restoring salivary function with a parasympathomimetic should result in the partial elimination of oxygen-free radicals, lipid peroxidation, and other oxidation debris, thus protecting the salivary glands and the oral mucosa. 39, 60 The chemotherapy patient has the advantage of far more functional salivary gland tissue than the H&N radiotherapy patient, and therefore a greater likelihood of salivary stimulation from pilocarpine. 61, 62 It has been proposed that saliva containing chemotherapeutic agent(s), or their metabolites, may cause mucositis through direct stomatotoxicity to the oral mucosa. 22, 63, 64 However, the correlation of concentrations of chemotherapeutic agents in saliva and plasma, and the impact of each on mucositis are controversial. 63, [65] [66] [67] Chemotherapyinduced reduction in salivary gland output could result in a decreased flushing of the chemotherapy metabolites from the mouth, resulting in an increased dose effect to the oral mucosa. Conversely, there is the theoretical risk of a pilocarpine-stimulated increase in mucosal exposure to saliva-containing chemotherapeutic agents or metabolites as well. 67 A limitation of prior studies of oral toxicity in chemoand/or radiotherapy patients is the lack of an agreed scoring system for oral mucositis. There is no single universally accepted tool for this purpose. Several scoring systems were available at the time this study was designed, and more have been created since. 46, 48, [68] [69] [70] [71] [72] However, all of them have limitations and are different enough to preclude comparison between studies. Some tools attempt to compare or combine objective, physical changes in mucosa with functional and subjective, qualitative measures. 68 Some lack a breakdown of oral anatomical sites, a definition of terms (eg, mild, moderate, and severe), and agreement on scoring for objective and subjective problems. Others are overly detailed, cumbersome, or require that clinical examinations be conducted by oral medicine experts. Our assessment tool evaluates three anatomical areas separately, and includes gingival mucositis, as this site often has a bacterial burden that can result in erythema, pain, swelling, bleeding, and infection during and following intensive chemotherapy. In addition, we gather subjective and objective assessments, and functional problems (eg, swallowing) separately. We also attempted to comply with recommendations on the construction of such tools. 73 For example, we have toxicity grades for chemotherapy-related problems that can be evaluated and scored both individually and in groups, as we did to compute a WHO score for comparison with other studies using this common tool.
The only other published, randomized, prospective trial of pilocarpine for chemotherapy patients included 32 subjects undergoing 82 courses of chemotherapy, which reported a significant reduction in the incidence and severity of mucositis, in contrast to our negative findings. 45 Of interest was our finding of a strong trend in the pilocarpine group to have an increased report of xerostomia and sleeping problems, the reasons for which are unclear. Since these results were at best only marginally significant, and multiple comparisons were utilized, the possibility of a type I error is more likely. Also, the actual differences were small and therefore of minimal clinical significance. Since our study was finalized, Papas et al 74 report that 7.5 mg pilocarpine has greater efficacy in Sjo¨gren's disease than the currently approved dose (5 mg) for H&N radiotherapy patients, and this larger dose could have a benefit in the setting of cancer chemotherapy as well.
In summary, despite previous, small clinical trials that suggest a benefit from pilocarpine in the prevention of mucositis in the H&N radiotherapy population, and one trial in a chemotherapy population, we found no evidence to support the use of pilocarpine for moderate oral mucositis in ABSCT patients.
